Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
View Patent ↗The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
1. An IgG Fc-containing polypeptide comprising an altered Fc region, wherein said Fc-containing polypeptide comprises at least one mutation within the Fc region as compared to a starting Fc-containing polypeptide and wherein the at least one mutation is a substitution at EU amino acid position 304 with aspartate or glutamate in combination with a second mutation selected from the group consisting of:
a substitution at EU amino acid position 284 with aspartate or glutamate;
a substitution at EU amino acid position 285 with aspartate or glutamate;
a substitution at EU amino acid position 286 with aspartate or glutamate;
a substitution at EU amino acid position 288 with a aspartate or glutamate;
a substitution at EU amino acid position 290 with aspartate or glutamate; and
a substitution at EU amino acid position 305 with aspartate or glutamate,
wherein the IgG Fc-containing polypeptide binds FcRn with different binding affinity compared to the starting polypeptide that does not contain the mutations.
2. The IgG Fc-containing polypeptide of claim 1 , wherein the polypeptide is an antibody or fragment thereof, the an antibody or fragment thereof comprising VL and VH domains, said VL and VH domains comprising complementarity determining regions (CDRs) which confer binding specificity on the antibody or fragment thereof.
3. The IgG Fc-containing polypeptide of claim 1 , wherein the polypeptide is a fusion protein.
4. The IgG Fc-containing polypeptide of claim 1 , wherein the Fc region is from a human IgG antibody.
5. The IgG Fc-containing polypeptide of claim 1 , wherein the starting polypeptide comprises the amino acid sequence of SEQ ID NO:2.
6. The IgG Fc-containing polypeptide of claim 2 , wherein the polypeptide comprises one or more non-human amino acids residues in a complementarity determining region (CDR) of said VL or VH domain.
7. The IgG Fc-containing polypeptide of claim 2 , wherein the polypeptide binds (a) an antigen and (b) an FcR.
8. The IgG Fc-containing polypeptide of claim 3 , wherein the polypeptide binds (a) a ligand and (b) an FcR.
9. The IgG Fc-containing polypeptide of claim 1 , wherein the altered polypeptide exhibits one binding affinity for the FcR at a first pH, and exhibits a different binding affinity for the FcR at a second pH.
10. The IgG Fc-containing polypeptide of claim 1 , wherein the altered polypeptide binds to Protein A or G.
11. A composition comprising the IgG Fc-containing polypeptide of claim 1 and a pharmaceutically-acceptable carrier.
12. The IgG Fc-containing polypeptide of claim 9 that exhibits an affinity for an FcRn at a first pH, and exhibits a different affinity for an FcRn at a second pH.
13. A composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier.
14. The IgG Fc-containing polypeptide of claim 2 , wherein the Fc region is from a human IgG antibody.
15. The IgG Fc-containing polypeptide of claim 3 , wherein the Fc region is from a human IgG antibody.
16. The IgG Fc-containing polypeptide of claim 2 , wherein the starting polypeptide comprises the amino acid sequence of SEQ ID NO:2.
17. The IgG Fc-containing polypeptide of claim 3 , wherein the starting polypeptide comprises the amino acid sequence of SEQ ID NO:2.